Arcus Biosciences, Inc.
RCUS
$8.62
$0.111.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.15% | -2.17% | 1.08% | -2,225.00% | 95.06% |
| Total Depreciation and Amortization | 0.00% | 50.00% | 0.00% | -33.33% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -6.67% | -6.25% | -55.56% | 157.14% |
| Change in Net Operating Assets | -60.87% | -122.77% | 631.58% | 48.65% | -54.17% |
| Cash from Operations | -32.00% | -484.62% | 127.66% | -4,600.00% | 97.73% |
| Capital Expenditure | 0.00% | 0.00% | -- | 100.00% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.54% | 285.71% | -144.44% | 138.18% | -585.29% |
| Cash from Investing | -37.25% | 275.86% | -146.03% | 137.28% | -703.57% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,633.33% | 50.00% | -33.33% | -98.69% | 7,533.33% |
| Repurchase of Common Stock | -- | -400.00% | 0.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,200.00% | -104.17% | 2,300.00% | -99.13% | 7,533.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 182.35% | -213.33% | 255.17% | -150.00% | 201.75% |